'Biologic products' presentation slideshows

Vaccine Update

Vaccine Update. William Atkinson, MD, MPH* Idaho Immunization Conference Boise, Idaho September 30 2013. *Representing the Immunization Action Coalition, Saint Paul, MN. Disclosures.

659 views • 50 slides

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH. By: Wysteria Hart Sahar Mohammadi. Who is CBER?. Governed by: Section 351 of the Public Health Service Act Sections of the Food Drug and Cosmetics Act. What is CBER?. Regulate biologic products Safe for use Effective

317 views • 14 slides

BIOSIMILARS- Regulatory Framework and Pipeline Analysis provides market dynamics, key players, therapy area, development phase, legal strategies, action mechanism, late stage products, competition prediction, indications, healthcare expenditure, trends, growth drivers, barriers, scope and a lot more.

265 views • 8 slides

BIOSIMILARS - Regulatory Framework and Pipeline Analysis

Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are getting the world wide attention as the cost of the innovative biologics are enormously high and even minimal reduction in price will reduce the healthcare spending substantially.

281 views • 6 slides